Repare Therapeutics Inc. (RPTX)
NASDAQ: RPTX · Real-Time Price · USD
2.215
-0.015 (-0.67%)
At close: Dec 5, 2025, 4:00 PM EST
2.130
-0.085 (-3.84%)
After-hours: Dec 5, 2025, 5:21 PM EST
Repare Therapeutics Revenue
Repare Therapeutics had revenue of $11.62M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $11.87M, down -82.16% year-over-year. In the year 2024, Repare Therapeutics had annual revenue of $53.48M with 4.58% growth.
Revenue (ttm)
$11.87M
Revenue Growth
-82.16%
P/S Ratio
7.98
Revenue / Employee
$92,016
Employees
129
Market Cap
95.21M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RPTX News
- 15 days ago - Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc. - Business Wire
- 17 days ago - Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewsWire
- 18 days ago - Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value - Benzinga
- 21 days ago - Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc. - Business Wire
- 7 weeks ago - Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Business Wire
- 4 months ago - Repare (RPTX) Q2 Loss Narrows 52% - The Motley Fool
- 4 months ago - Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - Business Wire
- 5 months ago - Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - Business Wire